Want to see SE:ICO full AI Analyst Report?

Iconovo AB (ICO) Price & Analysis

1 Followers

ICO Stock Chart & Stats

kr1.03

kr0.03(3.00%)

At close: Jul 31 4:00 PM EDT

kr1.03

kr0.03(3.00%)

Day’s Range― - ―

52-Week Rangekr0.87 - kr2.79

Previous CloseN/A

Volume15.90K

Average Volume (3M)46.24K

Market Cap

kr77.04M

Enterprise Valuekr45.03

Total Cash (Recent Filing)kr49.25M

Total Debt (Recent Filing)kr5.70M

Price to Earnings (P/E)―

Beta-0.32

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.93

Shares Outstanding74,800,380

10 Day Avg. Volume58,575

30 Day Avg. Volume46,237

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.37

Price to Sales (P/S)39.24

P/FCF Ratio-0.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.42

Revenue Forecast (FY)kr29.00M

Bulls Say, Bears Say

Bulls Say

Licensing/partnership ModelA partner/licensing business is capital-light and scales with external drug development. Upfront fees, milestones and royalties align Iconovo with partners' long development timelines, offering durable revenue levers as partner projects progress to clinical and commercialization stages.

Low Leverage Balance SheetVery low debt reduces refinancing risk and gives financial flexibility to fund device development and support partner programs. This cushion helps sustain operations through multi‑quarter partner timelines without immediate pressure from fixed financing costs.

TTM Revenue ReboundAn 18.8% TTM revenue rebound signals renewed partner activity or project wins. Because pharmaceutical device partnerships progress over months, sustained top‑line recovery can increase milestone visibility and improve future cash conversion if it persists.

Bears Say

Negative Gross Profit & Large LossesNegative gross profit means core unit economics are currently unfavorable; persistent operating losses erode equity and limit reinvestment. Over several quarters this undermines the company’s ability to self-fund development and increases reliance on external financing or partner advances.

Consistent Negative Cash FlowOngoing negative operating and free cash flow indicate structural cash burn. As burn persists, runway shortens and the company becomes dependent on external funding or milestone receipts, reducing strategic optionality and raising dilution or liquidity risk over months.

Small, Volatile Revenue & Negative ROESmall, volatile revenues tied to partner timing plus a roughly -34% ROE show the company is not generating returns on capital. This scale and performance handicap limit the firm's ability to absorb setbacks and makes long-term self-sustainability dependent on successful partner commercialization.

ICO FAQ

What was Iconovo AB’s price range in the past 12 months?

Iconovo AB lowest stock price was kr0.87 and its highest was kr2.79 in the past 12 months.

What is Iconovo AB’s market cap?

Iconovo AB’s market cap is kr77.04M.

When is Iconovo AB’s upcoming earnings report date?

Iconovo AB’s upcoming earnings report date is Aug 20, 2026 which is in 16 days.

How were Iconovo AB’s earnings last quarter?

Iconovo AB released its earnings results on Apr 24, 2026. The company reported -kr0.105 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.105.

Is Iconovo AB overvalued?

According to Wall Street analysts Iconovo AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Iconovo AB pay dividends?

Iconovo AB does not currently pay dividends.

What is Iconovo AB’s EPS estimate?

Iconovo AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Iconovo AB have?

Iconovo AB has 74,800,380 shares outstanding.

What happened to Iconovo AB’s price movement after its last earnings report?

Iconovo AB reported an EPS of -kr0.105 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.478%.

Which hedge fund is a major shareholder of Iconovo AB?

Currently, no hedge funds are holding shares in SE:ICO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Iconovo AB

Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.